Axis 3: Precision Oncology and AI

This Axis is focused on identifying targetable vulnerabilities in tumour cells and their microenvironments and exploiting these discoveries to empower precision medicine, particularly for cancers that impose a high clinical and societal burden, are aggressive and difficult to treat, or are rare and lack effective therapies. Clinician-scientists, surgeons and pathologists are deeply embedded as collaborators of this Axis, facilitating the development of new models and enabling access to patient samples and data, while allowing novel precision oncology strategies to be translated to the clinic. This includes a strong network of collaborators across multiple FRQ-funded Centres and Institutes, Thematic Networks including the Reseau du recherche en cancer (RRCancer), as well as national networks such as the TFRI Marathon of Hope Cancer Centres Network (MOHCCN), where the GCI plays a leading role. 

Axis lead: Ian Watson